Dasabuvir Sodium; Ombitasvir; Paritaprevir; Ritonavir Patent Expiration

Dasabuvir Sodium; Ombitasvir; Paritaprevir; Ritonavir is Used for treating HCV infection. It was first introduced by Abbvie Inc in its drug Viekira Xr on Jul 22, 2016.


Dasabuvir Sodium; Ombitasvir; Paritaprevir; Ritonavir Patents

Given below is the list of patents protecting Dasabuvir Sodium; Ombitasvir; Paritaprevir; Ritonavir, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Viekira Xr US10105365 Solid antiviral dosage forms Jan 02, 2035 Abbvie
Viekira Xr US10201541 Compositions and methods for treating HCV May 17, 2032 Abbvie
Viekira Xr US10201584 Compositions and methods for treating HCV May 17, 2032 Abbvie
Viekira Xr US7148359 Polymorph of a pharmaceutical Jul 19, 2019

(Expired)

Abbvie
Viekira Xr US7364752 Solid dispersion pharamaceutical formulations Nov 10, 2020

(Expired)

Abbvie
Viekira Xr US8188104 Anti-infective agents and uses thereof May 17, 2029 Abbvie
Viekira Xr US8268349 Solid pharmaceutical dosage form Aug 25, 2024 Abbvie
Viekira Xr US8399015 Solid pharmaceutical dosage form Aug 25, 2024 Abbvie
Viekira Xr US8420596 Macrocyclic hepatitis C serine protease inhibitors Apr 10, 2031 Abbvie
Viekira Xr US8466159 Methods for treating HCV Sep 04, 2032 Abbvie
Viekira Xr US8492386 Methods for treating HCV Sep 04, 2032 Abbvie
Viekira Xr US8501238 Anti-infective agents and uses thereof Sep 17, 2028 Abbvie
Viekira Xr US8642538 Macrocyclic hepatitis C serine protease inhibitors Sep 10, 2029 Abbvie
Viekira Xr US8680106 Methods for treating HCV Sep 04, 2032 Abbvie
Viekira Xr US8685984 Methods for treating HCV Sep 04, 2032 Abbvie
Viekira Xr US8686026 Solid compositions Jun 09, 2031 Abbvie
Viekira Xr US8691938 Anti-viral compounds Apr 13, 2032 Abbvie
Viekira Xr US9006387 Anti-viral compounds Jun 10, 2030 Abbvie
Viekira Xr US9044480 Compositions and methods for treating HCV Apr 10, 2031 Abbvie
Viekira Xr US9139536 Anti-infective agents and uses thereof Nov 09, 2028 Abbvie
Viekira Xr US9333204 Solid antiviral dosage forms Jan 02, 2035 Abbvie
Viekira Xr US9744170 Solid antiviral dosage forms Jan 02, 2035 Abbvie


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Dasabuvir Sodium; Ombitasvir; Paritaprevir; Ritonavir's patents.

Given below is the list recent legal activities going on the following patents of Dasabuvir Sodium; Ombitasvir; Paritaprevir; Ritonavir.

Event Date Patent/Publication
Patent litigations
Payment of Maintenance Fee, 12th Year, Large Entity 12 Oct, 2023 US8188104
Payment of Maintenance Fee, 8th Year, Large Entity 08 Feb, 2023 US9139536
Payment of Maintenance Fee, 8th Year, Large Entity 09 Nov, 2022 US9044480
Payment of Maintenance Fee, 8th Year, Large Entity 14 Sep, 2022 US9006387
Payment of Maintenance Fee, 4th Year, Large Entity 13 Jul, 2022 US10201541
Payment of Maintenance Fee, 4th Year, Large Entity 13 Jul, 2022 US10201584
Post Issue Communication - Certificate of Correction 10 May, 2022 US9744170
Email Notification 04 May, 2022 US9744170
Electronic Review 04 May, 2022 US9744170
Mail Certificate of Correction Memo 03 May, 2022 US9744170



Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳